Erytech Pharma

13 patents currently held · Updated Nov 14, 2026

2 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Apr 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 4, 2027
The maintenance fee for Anti-bacterial compositions and uses thereof (US 11,690,885) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
1 fee due Apr 10, 2027
The maintenance fee for Phage Therapy (US 11,779,617) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
1 fee due Oct 16, 2027
The maintenance fee for Phage therapy of E coli infections (US 11,957,724) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

2 terms have ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,125,876	Erythrocytes containing arginine deiminase In force Term ends Apr 23, 2027 · From the USPTO record	In force	Term ends Apr 23, 2027	From the USPTO record
US 10,780,151	Composition and therapeutic anti-tumour vaccine In force Term ends Sep 9, 2028 · From the USPTO record	In force	Term ends Sep 9, 2028	From the USPTO record
US 9,364,504	Compostition and therapeutic anti-tumour vaccine In force Term ends Apr 15, 2029 · From the USPTO record	In force	Term ends Apr 15, 2029	From the USPTO record
US 8,974,802	Medicament for the Treatment of Cancer of the Pancreas In force Term ends Oct 12, 2029 · High confidence	In force	Term ends Oct 12, 2029	High confidence
US 10,077,431	Phage therapy of pseudomonas infections In force Term ends Oct 24, 2034 · From the USPTO record	In force	Term ends Oct 24, 2034	From the USPTO record
US 10,260,051	Phage Therapy of Pseudomonas Infections In force Term ends Oct 24, 2034 · Medium confidence	In force	Term ends Oct 24, 2034	Medium confidence
US 10,918,680	Phage therapy of E coli infections In force Term ends Jan 9, 2035 · From the USPTO record	In force	Term ends Jan 9, 2035	From the USPTO record
US 10,780,126	Pharmaceutical Kit Comprising Erythrocytes Encapsulating a Plp-Dependent Enzyme and, a Non-Phosphate PLP Precursor In force Term ends Feb 12, 2035 · High confidence	In force	Term ends Feb 12, 2035	High confidence
US 10,898,530	Phage Therapy In force Term ends Jan 27, 2036 · High confidence	In force	Term ends Jan 27, 2036	High confidence
US 11,779,617	Phage Therapy In force Term ends Jan 27, 2036 · High confidence	In force	Term ends Jan 27, 2036	High confidence

10 of 13 patents shown.

Pro members see all 13.

Pro members: see all 13 patents

Also on record, not counted in the 13: 2 patents in force now held by others · 7 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 1 abandoned · 9 no status recorded

List them